title: [The prevalence and evolution of hypoacusis in Cooley's disease].
abstract: With the improved life expectation of patients with beta-thalassemia-major (BTM) or Cooley's Disease, new clinical problems, such as hearing damage, have emerged. The authors describe audiometric data of 50 patients with BTM. High-frequency thresholds were higher in BTM than those of a control group. Prevalence of hearing loss in BTM was 14-26%, depending on the frequency range considered, while in the control group it was between 4.3-19.1%. The prevalence of hearing loss in BTM with respect to that of the general population was 7-10% higher. Hearing loss ranged from mild to moderate. A good correlation was found between hearing loss and the cumulative dose of desferoxamine administered. These data were indicative of an ototoxic effect of this drug. Many patients (28.6%) showed significant hearing threshold deterioration after 3 years. On the light of these results, the authors suggest regular audiologic follow-up of patients with BTM.
authors.affiliation: Divisione ORL, Ospedale S. Caterina Novella, Galatina (LE).
authors.forename: D
authors.initials: D
authors.lastname: Cuda
authors.forename: M
authors.initials: M
authors.lastname: De Benedetto
authors.forename: M
authors.initials: M
authors.lastname: Leante
authors.forename: E
authors.initials: E
authors.lastname: Corvaglia
mesh_terms: D000293:Adolescent; D000328:Adult; D001299:Audiometry; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003676:Deferoxamine / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006311:Hearing Disorders / Q000175:diagnosis / Q000453:epidemiology* / Q000209:etiology; D006801:Humans; D007558:Italy / Q000453:epidemiology; D008297:Male; D015995:Prevalence; D013789:Thalassemia / Q000150:complications / Q000453:epidemiology* / Q000628:therapy
chemical_list: D003676:Deferoxamine
vernacular_title: Prevalenza ed evoluzione dell'ipoacusia nel morbo di Cooley.